REFERENCES

1. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Diseases. New York: Grune and Stratton, 1970:282-298
2. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet. 1993; 342:1340-1344. doi:10.1016/0140- 6736(93)92250-W
3. Antoniu E, Luca V. Features of clinical evolution of severe acute viral hepatitis. Series of 72 cases. Rev Med Chir Soc Med Nat Iasi. 2010; 114: 95-100. PMid:20509283
4. De Socio GV, Mercuri A, Di Candilo F, Baldelli F. Entecavir to treat severe acute hepatitis B. Scand J Infect Dis. 2009; 41: 703-704. doi:10.1080/00365540903062705 PMid:19544224
5. Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 2009;80:235–240
6. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006:4:1076-81
7. Lok ASF, McMahon BJ. AASLD Practice Guideline, Chronic Hepatitis B: Update of Recommendation 2009; 50:661-2.
8. Girke J, Wedemeyer H, Wiegand J, Manns MP, Tillmann HL. Acute hepatitis B: is antiviral therapy indicated? Two case reports. Dtsch Med Wochenschr. 2008; 133:1178- 1782. doi:10.1055/s-2008-1077235 PMid:18491273
9. Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, Roggendorf M, Gerken G, Canbay A. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion. 2009; 80:235-40. doi:10.1159/000236009 PMid:19828954
10. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC, Sarin SK. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007; 45:97-101. doi:10.1002/hep.21486 PMid:17187417
11. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010; 55: 775-783. doi:10.1007/s10620-009-1060-5 PMid:19957031
12. Lok A S F, McMahon BJ. Chronic Hepatitis B: Update 2009. AASLD practice guideline update. Hepatology 2009; 50: 661-662. doi:10.1002/hep.23190 PMid:19714720
13. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC, Sarin SK. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007; 45:97-101. doi:10.1002/hep.21486 PMid:17187417
14. EASL Clinical Practice Guidelines: management of chronic hepatitis B. European Association For The Study Of The Liver. J Hepatol. 2009; 50:227-42. doi:10.1016/j.jhep.2008.10.001 PMid:1905458
15. De Socio GV, Sgrelli A, Tosti A, Baldelli F: Severe acute hepatitis B treated with entecavir. Mediterr J Hematol Infect Dis 2011, 3(1):e2011010
16. Streinu-Cercel O, Streinu-Cercel A, Preotescu LL, Streinu-Cercel A: Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B. GERMS 2012, 2(1):18-22.